Celcuity Inc. is a publicly listed (NASDAQ: CELC) clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy.  Our mission is to extend the lives of cancer patients by leveraging our proprietary CELsignia platform to develop first-in-class therapies and companion diagnostics. 

Celcuity’s lead therapeutic candidate, gedatolisib, is a potential first-in-class pan-PI3K and mTOR inhibitor. Celcuity is currently planning to initiate a Phase 3 registration-enabling clinical trial to evaluate gedatolisib as a potential first-in-class treatment for patients with ER+/HER2-negative metastatic breast cancer.  Our CELsignia companion diagnostics are currently being evaluated in five clinical trials to assess whether breast cancer patients identified with a CELsignia test respond to a matching targeted therapy.